Merck & Co., Inc. (FRA:6MK)
75.00
-1.30 (-1.70%)
At close: Oct 23, 2025
Merck & Co. Revenue
Merck & Co. had revenue of $15.81B USD in the quarter ending June 30, 2025, a decrease of -1.90%. This brings the company's revenue in the last twelve months to $63.62B, up 1.82% year-over-year. In the year 2024, Merck & Co. had annual revenue of $64.17B with 6.74% growth.
Revenue (ttm)
$63.62B
Revenue Growth
+1.82%
P/S Ratio
3.48
Revenue / Employee
$848.21K
Employees
75,000
Market Cap
188.46B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 64.17B | 4.05B | 6.74% |
| Dec 31, 2023 | 60.12B | 832.00M | 1.40% |
| Dec 31, 2022 | 59.28B | 10.58B | 21.72% |
| Dec 31, 2021 | 48.70B | 7.19B | 17.31% |
| Dec 31, 2020 | 41.52B | 2.40B | 6.13% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Mercedes-Benz Group AG | 139.36B |
| Deutsche Telekom AG | 120.55B |
| Allianz SE | 109.02B |
| Siemens Aktiengesellschaft | 78.30B |
| Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München | 62.33B |
| Siemens Energy AG | 38.39B |
| SAP SE | 36.49B |
| Deutsche Bank Aktiengesellschaft | 30.07B |
Merck & Co. News
- 15 hours ago - eschbach's Shiftconnector® Helps Power Merck's Visual Factory to Drive Greater Transparency, Agility, and Supply Chain Resilience - PRNewsWire
- 16 hours ago - These low-risk stocks could be a profitable answer to this volatile earnings season - Market Watch
- 19 hours ago - Merck (MRK) Gains FDA Priority Review for Keytruda Combinations in Bladder Cancer - GuruFocus
- 20 hours ago - Merck to Present New Data from Its Innovative Cardio-Pulmonary Pipeline and Portfolio at AHA Scientific Sessions 2025 - Business Wire
- 20 hours ago - FDA Grants Priority Review For Merck's KEYTRUDA And KEYTRUDA QLEX SBLAs In MIBC - Nasdaq
- 21 hours ago - FDA Grants Priority Review for KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each in Combination with Padcev® (enfortumab vedotin-ejfv), for Certain Patients with Muscle-Invasive Bladder Cancer - Business Wire
- 1 day ago - Merck & Co Unusual Options Activity - Benzinga
- 2 days ago - Merck (MRK) Collaborates with Flare Therapeutics in Cancer Treatment Study - GuruFocus